Abstract: A vehicle includes: a travel state sensor configured to acquire information about a travel state of the vehicle; one or more processors; and a memory connected to the one or more processors and storing a plurality of instructions to be executed by the one or more processors. The instructions are configured to cause the one or more processors to: communicate with an autonomous driving device configured to calculate a target track for the vehicle; subject the vehicle to automated travel in accordance with the target track received from the autonomous driving device; and calculate an evaluation value of performance of the autonomous driving device based on the information acquired by the travel state sensor.

Abstract: The control device according to the present disclosure is configured to execute, in a process of stopping a vehicle in an emergency, acquiring occupant information including information on at least one of a state or an attribute of an occupant of the vehicle, acquiring traveling environment information of the vehicle, calculating an in-vehicle risk indicating a risk of damage to the occupant when the vehicle is decelerated by the first braking control based on the occupant information, calculating an out-of-vehicle risk indicating a risk of damage caused by the vehicle based on the traveling environment information, braking the vehicle by the second braking control with less deceleration than the first braking control while the in-vehicle risk is higher than the out-of-vehicle risk, and braking the vehicle by the first braking control when the out-of-vehicle risk is higher than the in-vehicle risk.

Abstract: A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, ?-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.).

Abstract: The present invention relates to a compound represented by formula (I), which has a GPR120 agonist action and thus is useful for treatment of diabetes mellitus or hyperlipidemia, or a pharmaceutically acceptable salt thereof. In the formula, (AA) represents a phenyl or the like, which may be substituted with a lower alkoxy group or the like; (BB) represents a divalent group or the like, derived by removal of two hydrogen atoms from a benzene which may be substituted with a halogen atom or the like; X represents a spacer having a main chain composed of 1-8 carbon atoms wherein 1-3 carbon atoms in the main chain may be substituted with an oxygen atom or the like; and Y represents a hydrogen atom or the like.

Abstract: Compounds of a formula (I) and their pharmaceutically-acceptable salts are disclosed. The compounds have glucokinase-activating effect and are therefore useful for treatment of diabetes and obesity. R1 and R2 each independently represent a lower alkyl group; X1 represent a group of a formula (II-1): wherein: R11 and R12 each independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they bond, R11 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be replaced by an oxygen atom), or taken together with a carbon atom in (CH2)m, R11 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring; m indicates an integer of from 1 to 3.

Abstract: A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R5 and R6 each represent a hydrogen atom, a lower alkyl group, etc.

Abstract: A manufacture method for an inner-fin tube includes a tube forming process for continuously forming a tube member joined at one end side thereof, an inner fin transferring process for continuously transferring an inner fin member, an inner fin twisting process for twisting the transferred inner fin member at at least two portions, and an inner fin inserting process for inserting the inner fin member into the tube member through the one end side thereof at the halfway stage of the tube forming process. At the inner fin twisting process, a transfer direction of the inner fin member is altered so that the inner fin member faces the one end side of the tube member and a longitudinal direction of a cross section (perpendicular to transfer direction thereof) of the inner fin member corresponds with a major axis direction of a flat cross section of the tube member.

Abstract: The present invention relates to a compound represented by the formula: or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently a lower alkyl group, X is CH or the like, and X1 is an aminoalkoxy group or the like, which has a glucokinase-activating effect and thus is useful in the treatment of diabetes, obesity, and the like.

Abstract: Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): [wherein X1 represents oxygen, etc., X2 represents oxygen, etc., R1 represents a group on Ring A such as alkylsulfonyl, etc., R2 represents C3-7 cyclic alkyl optionally substituted with a halogen, etc., R3 represents a substituent on Ring B such as lower alkyl, etc., formula (II): [Chemical Formula 1] represents 6- to 10-membered aryl, etc., and formula (III): [Formula 1] represents monocyclic or bicyclic heteroaryl optionally having on Ring B a substituent represented by R3 above, wherein the carbon atom of Ring B which is bonded to the nitrogen atom of the amide group of formula (I) forms a C?N bond with the nitrogen atom of the ring], as well as their pharmaceutically acceptable salts.

Abstract: The present invention relates to a compound represented by formula (I), which has a GPR120 agonist action and thus is useful for treatment of diabetes mellitus or hyperlipidemia, or a pharmaceutically acceptable salt thereof. In the formula, (AA) represents a phenyl or the like, which may be substituted with a lower alkoxy group or the like; (BB) represents a divalent group or the like, derived by removal of two hydrogen atoms from a benzene which may be substituted with a halogen atom or the like; X represents a spacer having a main chain composed of 1-8 carbon atoms wherein 1-3 carbon atoms in the main chain may be substituted with an oxygen atom or the like; and Y represents a hydrogen atom or the like.

Abstract: Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): [wherein X1 represents oxygen, etc., X2 represents oxygen, etc., R1 represents a group on Ring A such as alkylsulfonyl, etc., R2 represents C3-7 cyclic alkyl optionally substituted with a halogen, etc., R3 represents a substituent on Ring B such as lower alkyl, etc., formula (II): [Chemical Formula 1] represents 6- to 10-membered aryl, etc., and formula (III): [Formula 1] represents monocyclic or bicyclic heteroaryl optionally having on Ring B a substituent represented by R3 above, wherein the carbon atom of Ring B which is bonded to the nitrogen atom of the amide group of formula (I) forms a C?N bond with the nitrogen atom of the ring], as well as their pharmaceutically acceptable salts.

Abstract: Compounds represented by formula (I): as well as their pharmaceutically acceptable salts are disclosed. The compounds are useful as glucokinase activating agents for the treatment of diabetes and related conditions. Compositions and methods of treatment are also included.

Abstract: A method and system for preventing an unauthorized access to a network via a user computer. The system includes a memory containing an IP address of the user computer and a microprocessor. The microprocessor is programmed to terminate a connection between the user computer and the network when an originating IP address of a data packet received from the user computer does not match the IP address of the user computer contained in the memory. The method uses a user computer connected to a network and an access control system. It includes storing an IP address of the user computer in a memory of the access control system, receiving a data packet from the user computer, and comparing an originating IP address of the data packet with the IP address of the user computer stored in the memory. The method further includes denying the user computer an access to the network if the originating IP address of the data packet is different from the IP address of the user computer stored in the memory.

Abstract: A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R5 and R6 each represent a hydrogen atom, a lower alkyl group, etc.

Abstract: Compounds of a formula (I) and their pharmaceutically-acceptable salts are disclosed. The compounds have glucokinase-activating effect and are therefore useful for treatment of diabetes and obesity. R1 and R2 each independently represent a lower alkyl group; X1 represent a group of a formula (II-1): wherein: R11 and R12 each independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they bond, R11 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be replaced by an oxygen atom), or taken together with a carbon atom in (CH2)m, R11 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring; m indicates an integer of from 1 to 3.

Abstract: A manufacture method for an inner-fin tube includes a tube forming process for continuously forming a tube member joined at one end side thereof, an inner fin transferring process for continuously transferring an inner fin member, an inner fin twisting process for twisting the transferred inner fin member at at least two portions, and an inner fin inserting process for inserting the inner fin member into the tube member through the one end side thereof at the halfway stage of the tube forming process. At the inner fin twisting process, a transfer direction of the inner fin member is altered so that the inner fin member faces the one end side of the tube member and a longitudinal direction of a cross section (perpendicular to transfer direction thereof) of the inner fin member corresponds with a major axis direction of a flat cross section of the tube member.

Abstract: Compounds represented by formula (I): as well as their pharmaceutically acceptable salts are disclosed. The compounds are useful as glucokinase activating agents for the treatment of diabetes and related conditions. Compositions and methods of treatment are also included.

Abstract: A method and system for operation of a resilient closed communication network without a dedicated protection network segment. The method uses a resilient closed communication network with at least one communication ring. The method includes the steps of receiving a data packet from a first external network at a first distributing station connected to the network, identifying a second distributing station connected to the network from which the data packet is to be forwarded to a second external network, and determining functioning routes from the first distributing station to the second distributing station. The method also includes the steps of selecting an optimal route among the functioning routes and sending the data packet from the first distributing station to the second distributing station using the optimal route.

Abstract: A method and system for operation of a resilient closed communication network without a dedicated protection network segment. The method uses a resilient closed communication network with at least one communication ring. The method includes the steps of receiving a data packet from a first external network at a first distributing station connected to the network, identifying a second distributing station connected to the network from which the data packet is to be forwarded to a second external network, and determining functioning routes from the first distributing station to the second distributing station. The method also includes the steps of selecting an optimal route among the functioning routes and sending the data packet from the first distributing station to the second distributing station using the optimal route.

Abstract: A method and system for preventing an unauthorized access to the Internet by a user or a user computer based on authorization data. The method includes identifying an access by the user or the user computer at or before an entry point and receiving incoming authorization data associated with the access. It also includes analyzing the incoming authorization data using information contained in an authorization database to determine the access is authorized and blocking the access beyond the entry point if the access is not authorized. The system includes a memory containing an authorization database related to the user or the user computer and a microprocessor. The microprocessor is programmed to block an access beyond an entry point by the user or the user computer when an analysis of incoming authorization data received from the user or the user computer based on information contained in the authorization database indicates that the access is unauthorized.